| Year |
Citation |
Score |
| 2020 |
Yap TA, O'Carrigan B, Penney MS, Lim JS, Brown JS, de Miguel Luken MJ, Tunariu N, Perez-Lopez R, Rodrigues DN, Riisnaes R, Figueiredo I, Carreira S, Hare B, McDermott K, Khalique S, ... Williamson CT, et al. Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902404. PMID 32568634 DOI: 10.1200/JCO.19.02404 |
0.522 |
|
| 2018 |
Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, ... ... Williamson CT, et al. Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. Scientific Reports. 8: 10614. PMID 30006631 DOI: 10.1038/s41598-018-29043-z |
0.301 |
|
| 2018 |
Fleuren ED, Jones S, Frankum J, Williamson C, Menon M, Shipley J, Ashworth A, Graaf Wvd, Lord CJ. Abstract 2975: Synthetic lethality in synovial sarcoma: SS18-SSX fusions and DNA damage response (DDR) inhibitors Cancer Research. 78: 2975-2975. DOI: 10.1158/1538-7445.Am2018-2975 |
0.446 |
|
| 2016 |
Brandsma I, Williamson C, Lord C. Exploiting synthetic lethal interactions in DNA repair deficient tumour cells using ATR inhibition European Journal of Cancer. 69: S120. DOI: 10.1016/S0959-8049(16)32958-6 |
0.582 |
|
| 2015 |
Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, ... ... Williamson CT, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. The New England Journal of Medicine. 373: 1697-1708. PMID 26510020 DOI: 10.1056/Nejmoa1506859 |
0.315 |
|
| 2012 |
Williamson CT, Kubota E, Hamill JD, Klimowicz A, Ye R, Muzik H, Dean M, Tu L, Gilley D, Magliocco AM, McKay BC, Bebb DG, Lees-Miller SP. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. Embo Molecular Medicine. 4: 515-27. PMID 22416035 DOI: 10.1002/Emmm.201200229 |
0.474 |
|
| 2010 |
Williamson CT, Muzik H, Turhan AG, Zamò A, O'Connor MJ, Bebb DG, Lees-Miller SP. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Molecular Cancer Therapeutics. 9: 347-57. PMID 20124459 DOI: 10.1158/1535-7163.MCT-09-0872 |
0.347 |
|
| 2009 |
Williamson LM, Williamson CT, Lees-Miller SP. DNA Double strand break repair: Mechanisms and therapeutic potential The Dna Damage Response: Implications On Cancer Formation and Treatment. 157-177. DOI: 10.1007/978-90-481-2561-6_8 |
0.632 |
|
| Show low-probability matches. |